In the treatment of pregnant women, we can use neither standard, breast-cancer-specific immunohistochemical targets, such as hormone receptor or HER2 antigen positivity, nor targets derived from genomic analysis, such as PIK3 (phosphatidylkinase 3) or ESR1 (gene for estrogen receptor 1) mutations, nor those found by pathologists (TILs (tumor infiltrating lymphocytes)). Here, ERBB2 is linked to breast carcinoma.